| scholarly article | Q13442814 |
| P50 | author | Alan S. Perelson | Q55719625 |
| Jeremie Guedj | Q56424041 | ||
| George M. Shaw | Q78514357 | ||
| Erica H Parrish | Q114423041 | ||
| Ruy M. Ribeiro | Q30504775 | ||
| Bette Korber | Q30505218 | ||
| Gerald H Learn | Q54541884 | ||
| Beatrice H. Hahn | Q55293537 | ||
| Tanmoy Bhattacharya | Q55414889 | ||
| P2093 | author name string | Hui Li | |
| Shuyi Wang | |||
| Mark B Stoddard | |||
| P2860 | cites work | A stochastic model of cytotoxic T cell responses | Q57213454 |
| "Lifespan" of liver cells. Autoradio-graphic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats | Q79064331 | ||
| Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study | Q83184829 | ||
| Mutational fitness effects in RNA and single-stranded DNA viruses: common patterns revealed by site-directed mutagenesis studies | Q22065913 | ||
| Rates of molecular evolution in RNA viruses: a quantitative phylogenetic analysis | Q24498689 | ||
| Viral mutation rates | Q24611162 | ||
| Wide range of quasispecies diversity during primary hepatitis C virus infection | Q27469430 | ||
| In situ distribution of hepatitis C virus replicative-intermediate RNA in hepatic tissue and its correlation with liver disease | Q27469626 | ||
| Characterization of cell lines carrying self-replicating hepatitis C virus RNAs | Q27469765 | ||
| Effect of alpha interferon on the hepatitis C virus replicon | Q27469963 | ||
| Quantitative Analysis of the Hepatitis C Virus Replication Complex | Q27472670 | ||
| Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells | Q27478039 | ||
| Superinfection Exclusion in Cells Infected with Hepatitis C Virus | Q27478378 | ||
| Dynamics of Hepatitis C Virus Replication in Human Liver | Q27478394 | ||
| Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes | Q27480348 | ||
| Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution | Q27486234 | ||
| Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo | Q27488394 | ||
| Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy | Q27860724 | ||
| Replication of hepatitis C virus | Q27860957 | ||
| Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing | Q28482493 | ||
| From molecular genetics to phylodynamics: evolutionary relevance of mutation rates across viruses | Q28483231 | ||
| Rates of evolutionary change in viruses: patterns and determinants | Q29616174 | ||
| Immunology of hepatitis B virus and hepatitis C virus infection | Q29618957 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase | Q29619994 | ||
| Course and outcome of hepatitis C | Q29620057 | ||
| Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection | Q30407004 | ||
| Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis | Q33592278 | ||
| Estimating time since infection in early homogeneous HIV-1 samples using a poisson model | Q33727328 | ||
| Quasispecies in viral persistence and pathogenesis of hepatitis C virus | Q33739366 | ||
| Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. | Q33877425 | ||
| Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection | Q33877481 | ||
| Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect | Q34022149 | ||
| The origin and evolution of hepatitis viruses in humans | Q34189077 | ||
| Distribution of spontaneous mutants and inferences about the replication mode of the RNA bacteriophage phi6. | Q34333217 | ||
| Rapid emergence of protease inhibitor resistance in hepatitis C virus | Q34551913 | ||
| Modelling viral and immune system dynamics | Q34572224 | ||
| Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. | Q35012057 | ||
| Mathematical modeling of viral kinetics: a tool to understand and optimize therapy | Q35105712 | ||
| Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance | Q35650866 | ||
| The role of cells refractory to productive infection in acute hepatitis B viral dynamics | Q35691056 | ||
| Upper limits of normal for alanine aminotransferase activity in the United States population | Q35713666 | ||
| Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C | Q35986301 | ||
| Modeling sequence evolution in acute HIV-1 infection | Q37384535 | ||
| Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes | Q40488747 | ||
| High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression | Q40685050 | ||
| Replication mode and landscape topology differentially affect RNA virus mutational load and robustness | Q42059089 | ||
| Modelling how ribavirin improves interferon response rates in hepatitis C virus infection | Q42989468 | ||
| Visualizing hepatitis C virus infections in human liver by two-photon microscopy | Q42989638 | ||
| Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production | Q42991802 | ||
| Dynamics of viremia in early hepatitis C virus infection | Q42992916 | ||
| Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. | Q42993927 | ||
| Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin | Q43048292 | ||
| From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity | Q43048808 | ||
| An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. | Q43049197 | ||
| The frequency distribution of spontaneous bacteriophage mutants as evidence for the exponential rate of phage reproduction | Q45203828 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 8 | |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | e1002881 | |
| P577 | publication date | 2012-08-23 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate | |
| P478 | volume | 8 |
| Q28537708 | A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity |
| Q52653197 | Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. |
| Q64082020 | Building a mechanistic mathematical model of hepatitis C virus entry |
| Q34802167 | Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin |
| Q38735317 | Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection |
| Q26828727 | Curing a viral infection by targeting the host: the example of cyclophilin inhibitors |
| Q36330328 | Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification |
| Q43065263 | Determination of spontaneous mutation frequencies in measles virus under nonselective conditions |
| Q42611326 | Diagnostically untypable hepatitis C virus variants: it is time to resolve the problem |
| Q40041222 | Different rates of spontaneous mutation of chloroplastic and nuclear viroids as determined by high-fidelity ultra-deep sequencing |
| Q38826176 | Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights |
| Q40858663 | Editorial on "Broadly neutralizing antibodies abrogate established hepatitis C virus infection" published in Science Translational Medicine on 17th September 2014 |
| Q28482493 | Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing |
| Q42993136 | Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis |
| Q52375192 | Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. |
| Q33629597 | Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals. |
| Q90166311 | Evaluation of haplotype callers for next-generation sequencing of viruses |
| Q27468696 | Exceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus Infection |
| Q28548089 | Extremely High Mutation Rate of HIV-1 In Vivo |
| Q34137544 | Generation and characterization of influenza A viruses with altered polymerase fidelity |
| Q26801759 | Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design |
| Q63684280 | Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing |
| Q63684287 | Genomic variability of within-host hepatitis C variants in acute infection |
| Q26801602 | HCV Kinetic Models and Their Implications in Drug Development |
| Q45323939 | HIV-1 and Hepatitis C virus selection bottleneck in Chinese people who inject drugs |
| Q65002126 | Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? |
| Q36645517 | Hepatitis C viral kinetics: the past, present, and future |
| Q38849307 | Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors |
| Q26853500 | Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy |
| Q40757862 | Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals |
| Q27468916 | Hepatitis C virus: Promising discoveries and new treatments |
| Q57164153 | Herpes simplex virus-2 dynamics as a probe to measure the extremely rapid and spatially localized tissue-resident T-cell response |
| Q92188161 | High multiplicity infection following transplantation of hepatitis C virus-positive organs |
| Q39442707 | Highly heterogeneous mutation rates in the hepatitis C virus genome |
| Q53820041 | Hsp90 shapes protein and RNA evolution to balance trade-offs between protein stability and aggregation. |
| Q35172385 | Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4 |
| Q34504820 | Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes |
| Q59354172 | Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era |
| Q36837502 | Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration |
| Q38634551 | Issues in vaccinology: Present challenges and future directions |
| Q27468616 | Lamivudine/Adefovir Treatment Increases the Rate of Spontaneous Mutation of Hepatitis B Virus in Patients |
| Q28067235 | Mechanisms of viral mutation |
| Q38256890 | Metabolomics technology and their application to the study of the viral infection. |
| Q38952060 | Modeling Viral Spread |
| Q26864673 | Modelling hepatitis C therapy--predicting effects of treatment |
| Q59357098 | Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection |
| Q45325775 | Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. |
| Q63740385 | Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs |
| Q90709061 | N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3 |
| Q42174637 | Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations |
| Q45324383 | Novel Synthesis and Phenotypic Analysis of Mutant Clouds for Hepatitis E Virus Genotype 1. |
| Q36558964 | Rapid hepatitis C virus divergence among chronically infected individuals. |
| Q28545971 | Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection |
| Q34594986 | Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization |
| Q64966359 | Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. |
| Q40732189 | Similarities between Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Genetic and Phenotypic Protease Quasispecies Diversity |
| Q36433960 | Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification |
| Q90460876 | Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses |
| Q56398203 | Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence |
| Q36158391 | Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir |
| Q44757794 | The 5BSL3.2 Functional RNA Domain Connects Distant Regions in the Hepatitis C Virus Genome |
| Q40960413 | The external domains of the HIV-1 envelope are a mutational cold spot |
| Q30583856 | Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling |
| Q30370595 | Viral diversity and clonal evolution from unphased genomic data. |
| Q26824655 | Viral kinetic modeling: state of the art |
| Q38735359 | Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. |
Search more.